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Background: Glucocorticoids as well as mineralocorticoid have been shown to play essential roles in the regula-
tion of electrical and mechanical activities in cardiomyocytes. Excess of these hormones is an independent risk
factor for cardiovascular disease. Intracellular sodium ([Na+]i) kinetics are involved in cardiac diseases, including
ischemia, heart failure and hypertrophy. However, intrinsic mediators that regulate [Na+]i in cardiomyocytes
have not been widely discussed. Moreover, the quantitative estimation of altered [Na+]i in cultured
cardiomyocytes and the association between the level of [Na+]i and the severity of pathological conditions,
such as hypertrophy, have not been precisely reported.
Methods and results: We herein demonstrate the quantitative estimation of [Na+]i in cultured neonatal rat
cardiomyocytes following 24 h of treatment with corticosterone, aldosterone and dexamethasone. The physio-
logical concentration of glucocorticoids increased [Na+]i up to approximately 2.5 mM (an almost 1.5-fold in-
crease compared to the control) in a dose-dependent manner; this effect was blocked by a glucocorticoid
receptor (GR) antagonist but not a mineralocorticoid receptor antagonist. Furthermore, glucocorticoids induced
cardiac hypertrophy, and the hypertrophic gene expression was positively and signiﬁcantly correlated with the
level of [Na+]i. Dexamethasone induced the upregulation of Na+/Ca2+ exchanger 1 at the mRNA and protein
levels.
Conclusions: The physiological concentration of glucocorticoids increases [Na+]i via GR. The dexamethasone-
induced upregulation of NCX1 is partly involved in the glucocorticoid-induced alteration of [Na+]i in
cardiomyocytes. These results provide new insight into the mechanisms by which glucocorticoid excess within
a physiological concentration contributes to the development of cardiac pathology.liabi
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The sodium ion (Na+) is the primary determinant of the distribution
of body ﬂuids. While the extracellular Na+ ([Na+]o) is ~140 mM, the
concentration of free intracellular Na+ ([Na+]i) is normally 4–16 mM,
as exquisitely maintained by a series of ion channels and transporters
[1–6]. This transsarcolemmal Na+ gradient is a key regulator of various
intracellular ions and metabolites. In the heart, [Na+]i has been shownlity and freedom from bias
ent of Internal Medicine,
i, Minato-ku, Tokyo 105-
Ltd. This is an open access articlto increase in the presence of cardiac diseases, including ischemia,
heart failure and hypertrophy [2–6]. Although the molecular mecha-
nisms bywhich [Na+]i increases in pathological conditions and the caus-
al relationship between [Na+]i and cardiac disease remain controversial,
some reports have suggested that elevated [Na+]i induces unfavorable
effects in cardiomyocytes. For example, an ionophore monensin, which
transports ions across the cell membrane and increases [Na+]i, has
been reported to activate the hypertrophic gene expression via salt-
inducible kinase 1 (SIK1), a kinase known to be critical for cardiac devel-
opment, in amyocyte cell line [7]. On the other hand, elevated [Na+]i in-
creases themitochondrial formation of reactive oxygen species in failing
cardiacmyocytes [8,9].Moreover, a rise in [Na+]i reduces Ca2+ extrusion
via the Na+/Ca2+ exchanger (NCX), which induces diastolic Ca2+ over-
load [5]. These reports suggest that elevated [Na+]i in cardiomyocytes
is a trigger for the development of pathological conditions in the heart.
Corticosteroids, including aldosterone and cortisol (in humans)/
corticosterone (in rodents), regulate the absorption of sodium ions ine under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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alocorticoid receptor (MR). An excess of these hormones induces sodi-
um retention, thereby causing hypertension [10,11]. Moreover, high
levels of cortisol and aldosterone are known to be independent risk fac-
tors for cardiovascular events [11–13]. This may be partly due to the di-
rect alteration of mineralocorticoid receptor (MR) signaling in the
cardiovascular system in addition to secondary systemic activities of
these hormones, such as the induction of hypertension, as MR antago-
nists are responsible for marked prognostic improvements in patients
with heart failure [14–16]. In cardiomyocytes, MR is expressed, while
11beta-hydroxysteroid dehydrogenase type 2, which converts gluco-
corticoids to their inactive metabolites, is not [17,18]. Hence, under
physiological conditions, most MRs are presumably occupied by
cortisol/corticosterone. On the other hand, glucocorticoid receptor
(GR), which displays high sequence homologywithMR and binds gluco-
corticoids with higher afﬁnity than the mineralocorticoid aldosterone, is
also expressed in cardiomyocytes. However, the role of speciﬁc GR sig-
naling in the cardiovascular system is poorly understood.
We and others have recently reported that aldosterone induces
[Na+]i elevation in cultured cardiomyocytes and that this effect is
rapid and non-genomic and occurs in a mineralocorticoid receptor-
independent fashion [19,20]. Although there is a previous report that
24-hour treatment with aldosterone activates Na+/H+ exchange
(NHE) and increases [Na+]i in cardiomyocytes using a sodium ﬂuores-
cent indicator [21], the absolute value of the alteration in [Na+]i is not
available. To our knowledge, the effects of glucocorticoid/GR signaling
on [Na+]i handling in cardiomyocytes have not been previously
reported. Moreover, the relationship between the severity of a patho-
logical status, such as cardiac hypertrophy, and the level of [Na+]i in
cardiomyocytes has not been discussed.
The present study was conducted to identify the role of corticoste-
roids, including corticosterone, aldosterone and synthesized glucocorti-
coid dexamethasone, in the regulation of [Na+]i in cardiomyocytes. The
results suggest that NCX1 is involved, at least in part, in the pathogene-
sis of altered sodium ion handling under conditions of glucocorticoid
excess via the GR pathway.2. Materials and methods
2.1. Reagents
Corticosterone, dexamethasone, eplerenone and RU486 were pur-
chased from Sigma-Aldrich. Aldosterone was purchased from WakoFig. 1. In vivo calibration of SBFI. The in vivo calibration of SBFI was accomplished by
exposing NRVM to various extracellular [Na+]. Between 0 and 20 mM [Na+]i, the SBFI
ﬂuorescence ratio (F340/F380) exhibited a linear relationship with [Na+]i (R2 = 0.998,
P b 0.0001).
Fig. 2. Corticosteroids increase [Na+]i via GR in NRVM. NRVM were treated with cortico-
sterone, aldosterone and dexamethasone at concentrations of 1 to 1000 nM in the pres-
ence or absence of 1 μM of RU486 or 10 μM of eplerenone for 24 h. The quantitative
estimation of [Na+]i was carried out after treatment. A: corticosterone, aldosterone and
dexamethasone increased [Na+]i in a dose-dependent manner. The data represent the
mean ± SEM of six to nine independent experiments. B: the corticosterone-induced
[Na+]i elevation was blocked by RU486 but not eplerenone. The data represent the
mean ± SEM of seven independent experiments. Cort, 100 nM of corticosterone; Epl,
10 μM of eplerenone; RU, 1 μM of RU486. *P b 0.05 versus control group, †P b 0.05.
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acetoxymethylester (SBFI-AM) and Pluronic F-127 were purchased
from Invitrogen. All primer sets for PCR were purchased from Applied
Biosystems. Antibodies were purchased from the following companies:
anti-NCX1 (Abcam); anti-NHE-1 (Santa Cruz Biotechnology); and anti-
β-actin (Sigma-Aldrich).
2.2. Cell culture
All animal procedures conformed to the National Institutes of
Health Guide for the Care and Use of Laboratory Animals and were ap-
proved by the Animal Research Committee of Jikei University. NeonatalFig. 3. Corticosteroids induce hypertrophy in NRVM. ThemRNA levels of the cardiac hypertroph
normalized to GAPDH (A and B). A: NRVMwere treated with the indicated dose of corticoster
independent experiments. B: NRVM were treated with 100 nM of corticosterone in the presen
mean± SEM of seven independent experiments. Cort, 100 nM of corticosterone; Epl, 10 μMof
microscopic images of NRVM treated with 100 nM of dexamethasone in the presence or absenrat ventricular myocytes (NRVM) were isolated from 1- to 3-day-old
Sprague–Dawley rats according to the manufacturer's protocol
fromWorthington Biochemical. Puriﬁed NRVMwere plated at a density
of 1 ∗ 105 cells/well in 96-well clear bottom plates (Greiner) in low-
glucose (1000 mg/l) DMEM (Invitrogen) supplemented with 5% fetal
bovine serum (Invitrogen), 10% horse serum (Invitrogen), 20 mM
HEPES, 200 μmol/l of bromodeoxyuridine, and antibiotics (100 U/ml
of penicillin G and 100 μg/ml of streptomycin). The cells were allowed
to attach at 37 °C in a 5% CO2 atmosphere, and subconﬂuent myocyte
monolayers were obtained after 48–72 h. Sixteen hours before treat-
ment with the indicated agents, the medium was replaced with
DMEM supplemented with 1% bovine serum albumin (Sigma-Aldrich).ic marker genes BNP, SKA and β-MHC in NRVMwere determined using real-time PCR and
one, aldosterone and dexamethasone for 48 h. The data represent the mean ± SEM of six
ce or absence of 1 μM of RU486 or 10 μM of eplerenone for 48 h. The data represent the
eplerenone; RU, 1 μMof RU486. *P b 0.05 versus control group, †P b 0.05. C: representative
ce of 1 μM of RU486.
Fig. 3 (continued).
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We measured [Na+]i in NRVM using a microplate reader as previ-
ously reported with some modiﬁcations [22–25]. Brieﬂy, NRVM were
loaded with 5 μM of SBFI-AM dissolved in DMEM supplemented with
1% bovine serum albumin for 3 h at 37 °C in the presence of the non-
ionic surfactant, Pluronic F-127 (0.05% w/v). After washing out the ex-
ternal dye three times with Tyrode's solution (150 NaCl, 5.4 KCl, 1.2
MgCl2, 0.4 NaH2PO4, 10 HEPES, 5 glucose and 1 CaCl2, pH 7.4) in the
presence of 1 mM of probenecid, leaving a ﬁnal volume of 100 μl in
each well, the ﬂuorescence intensity was measured using an Inﬁnite
200 PRO microplate reader (TECAN) at room temperature. Dual excita-
tionmeasurements at 340 nmand 380 nmwere obtained, and the emit-
ted ﬂuorescence was recorded at 510 ± 12.5 nm in the ﬂuorescence
bottom reading mode. The completion of hydrolysis was judged based
on the attainment of a stable 340/380 nm ratio. The microplate reader
is able to obtain measurements in each well of a plate within 90 s, and
the ﬂuorescence intensity was automatically recorded every 10 min.
In eachmicroplate, NRVMof the same preparation in 10wellswere pre-
pared in the absence of SBFI to measure the background signals of the
NRVM and microplates. The mean ﬂuorescence signals from the 10
SBFI-unloaded wells at 340 nm and 380 nm were subtracted from the
individual signals of the SBFI-loaded wells at each wavelength [22].2.4. In vivo calibration of SBFI
The in vivo calibration of SBFI was accomplished, similar to that
described in previous reports, by exposing the cardiomyocytes to var-
ious concentrations of extracellular [Na+] (0–20 mM) in the presence
of 1 mg/l Gramicidin D (MP Biomedicals), 100 μM of strophanthidin
(Sigma-Aldrich) and 2 mM EGTA, and the pH was adjusted to 7.1
with Tris base [22–25]. The solutions were prepared by mixing two
solutions of equal ionic strength. One solution contained 145 mM
Na+ (30 mM NaCl, 115 mM sodium gluconate) without K+, while
the other contained 145 mM K+ (30 mM KCl, 115 mM potassiumgluconate) without Na+. Calibration was performed at the end of
each experiment.
2.5. Real-time PCR
Total RNA was extracted from cardiomyocytes cultured in 12-well
plates using the PureLink RNeasymini Kit (Applied Biosystems) accord-
ing to the manufacturer's instructions. Two-step PCR was performed
with TaqMan Reverse Transcription Reagents and a TaqMan Universal
Master Mix Kit and quantiﬁed with the StepOne Real-time PCR system
(Applied Biosystems). The expression of each gene was normalized
to the level of GAPDH, which was stable under our experimental
conditions.
2.6. Immunoblotting
Whole cell extracts were prepared in cell lysis buffer (Cell Signaling)
and phenylmethylsulfonyl ﬂuoride on ice and boiled LDS sample buffer
(Novex). Equivalent amounts of protein were separated on 4–12% bis–
Tris gel (Invitrogen) and electrically transferred to nitrocellulose or
polyvinyl diﬂuoride membranes (Invitrogen). The membranes were
blocked with starting block (Thermo Fisher scientiﬁc) for 30 min at
room temperature and incubated with primary antibodies overnight
at 4 °C. The membranes were then washed with Tris-buffered saline
with Tween 20, incubated with the appropriate secondary antibodies
for 45 min at room temperature and developed using an enhanced
chemiluminescence method according to the manufacturer's protocol
(Thermo Fisher Scientiﬁc).
2.7. Statistical analysis
The data are expressed as the mean± standard error of the indicat-
ed number of experiments. The statistical analyses were performed
using Student's t test and one way ANOVA, followed by Tukey's test.
Values of P b 0.05 were considered to be signiﬁcant.
Fig. 4.Association between [Na+]i andmarkers of cardiac hypertrophy. NRVMwere treat-
ed with vehicle, corticosterone, aldosterone and dexamethasone at concentrations of 1 to
1000 nM in the presence or absence of 1 μMof RU486 or 10 μMof eplerenone for 48 h. The
relationship between [Na+]i and the hypertrophic gene expressionwas analyzed by using
a linear regression analysis. The coefﬁcient of determination (R2) and P value are indicated
in each panel.
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3.1. Corticosteroids increase [Na+]i in NRVM via GR
Fig. 1 shows a typical in vivo calibration experiment for SBFI in
NRVM. Between 0 and 20 mM [Na+]i, the SBFI ﬂuorescence ratio
(340/380 nm) exhibited a linear relationship with [Na+]i (coefﬁcient
correlation (R2) of 0.998, P b 0.0001). The value of [Na+]i in untreated
NRVM calculated using our method was 6.1 ± 0.1 mM (n = 30). To
examine the long-term effects of corticosteroids on [Na+]i, cardio-
myocyteswere treatedwith corticosterone, aldosterone and dexameth-
asone at a (patho)physiological concentration ranging from 1 to
1000 nM each. As shown in Fig. 2A, corticosterone, aldosterone and
dexamethasone increase [Na+]i in a dose-dependent manner, while
dexamethasone has 10 times the potency of corticosterone and 100
times the potency of aldosterone. These data suggest that GR is involved
in altered [Na+]i handling, in accordance with the ﬁndings of previous
reports showing the afﬁnity of steroids to the GR [26–28]. The maxi-
mum increase in [Na+]i in cardiomyocytes induced by these steroid
agents was approximately 2.5 mM (an almost 1.5-fold increase com-
pared to the control).
In order to examine the importance of GR signaling in the
corticosteroid-induced [Na+]i increase, we employed a GR antagonist,
RU486, and an MR antagonist, eplerenone. Treatment with 1 μM of
RU486 abolished the increase in [Na+]i induced by100nMof corticoste-
rone, which bound to both GR and MR in the cardiomyocytes, although
10 μM of eplerenone showed no effects (Fig. 2B). These results indicate
that GR is required for altered [Na+]i handling in cardiomyocytes treat-
ed with corticosteroids.
3.2. Corticosteroids induce cardiac hypertrophy via GR
As shown in Fig. 3A, corticosteroids induced the hypertrophic gene
expression, including that of B-type natriuretic peptide (BNP), skeletal
muscle alpha-actin (SKA) and beta-myosin heavy chain (β-MHC), in a
dose-dependent manner. These effects were blocked by 1 μM of RU
486 but not 10 μM of eplerenone (Fig. 3B). Fig. 3C shows the changes
in cell morphology of NRVM treated with 100 nM of dexamethasone
in the presence or absence of 1 μM of RU486. Dexamethasone induced
a marked increase in the cell surface area; this effect was abrogated by
RU486, compatible with the results showing that corticosteroids induce
the hypertrophic gene expression, and the ﬁndings of previous reports
by others regarding the effects of glucocorticoids on morphological
changes in cardiomyocytes [26,29].
3.3. Close association between [Na+]i and the cardiac hypertrophic gene
expression levels in NRVM treated with corticosteroids
As shown in Fig. 4, a close and signiﬁcant positive association was
observed between the level of [Na+]i and the hypertrophic gene expres-
sion in NRVM treatedwith the indicated corticosteroids. This ﬁnding in-
dicates that the extent of altered [Na+]i is associatedwith the severity of
pathophysiological conditions, such as hypertrophy, in cardiomyocytes.
3.4. NCX1 mRNA is induced by dexamethasone
In order to determine themechanisms underlying the glucocorticoid-
induced elevation of [Na+]i, we investigated the effects of dexametha-
sone on the expression of transporters that handle Na+ inﬂux in
cardiomyocytes. Fig. 5A shows the mRNA expressions of NCX1, NHE-1
and Na+/K+/2Cl− cotransporter 1 (NKCC1), the main transporters that
inﬂux Na+ in cardiomyocytes [1]. Forty-eight hours of treatment with
dexamethasone induced the NCX1 expression at the mRNA and protein
levels in a dose-dependentmanner; this effect was abrogated by 1 μMof
RU-486 (Fig. 5A). A higher concentration of dexamethasone signiﬁcantlyreduced the NHE-1 mRNA expression. On the other hand, the NKCC1
mRNA expression was not changed by treatment with dexamethasone.
3.5. NCX1 proteins are induced by dexamethasone
The protein level of NCX1was induced by treatmentwith 100 nMof
dexamethasone; this effect was blocked by 1 μMof RU486, according to
the mRNA expression. On the other hand, the NHE-1 protein level was
not changed by treatment with dexamethasone (Fig. 5B). Dexametha-
sone induced the upregulation of NCX1 at the mRNA level after 12 h
and at the protein levels after 18 h (Fig. 5C).
4. Discussion
In the present study, we found that chronic physiological concentra-
tions of glucocorticoid treatment increased [Na+]i in a dose-dependent
manner in NRVM up to approximately 2.5 mM (an almost 1.5-fold
54 D. Katoh et al. / IJC Heart & Vessels 3 (2014) 49–56increase compared to the control) quantiﬁed using the sodium ﬂuores-
cent indicator SBFI and in vivo calibration method. Supraphysiological
concentrations (higher than 100 nM) of aldosterone also increased[Na+]i. Furthermore, we conﬁrmed that these effects were abrogated
by a GR antagonist, but not anMR antagonist, suggesting that GR signal-
ing is essential for [Na+]i handling in cardiomyocytes.
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mones) in altering [Na+]i handling. For example, hyperthyroidism in-
creases [Na+]i and affects the expression of Na+ channels, NCX and
NHE [30]. On the other hand, α1- or β-adrenoceptor stimulation re-
duces [Na+]i [31–33]. We and others have previously reported that al-
dosterone rapidly induces [Na+]i elevation in cultured cardiomyocytes
in an MR-independent fashion [19,20]. Others have also reported that
24 h of treatment with 100 nM of aldosterone activates NHE-1 at the
protein level in cardiomyocytes via MR and increases [Na+]i measured
according to the sodium indicator, sodium green [21]. However, the ab-
solute value of the aldosterone-induced alteration in [Na+]i remains un-
clear because no calibration methods were used in these studies.
Furthermore, the variable dye concentrations in the cells and/or the
cell size may affect the intensity of ﬂuorescent indicator sodium green
due to its single excitation measurements [20,21]. Even minor changes
in global [Na+]i have a large impact on the cell function, primarily be-
cause small increases in [Na+]i affect Ca2+ ﬂuxes through NCX, and
the force of contraction has been reported to double with as little as a
1-mM increase in [Na+]i [34]. Therefore, the accuracy of measurements
of [Na+]i is critical in studies of [Na+]i in cardiomyocytes. In the present
study, we measured [Na+]i in NRVM using a microplate reader and
employed in vivo calibration of SBFI, which exhibited adequate accura-
cy, comparable to that of the traditional microscopy-based method
(Fig. 1). The value of [Na+]i in untreated quiescent NRVM calculated
using our method was 6.1 ± 0.1 mM, similar to the ﬁndings ranging
from 5 to 13 mM in previous reports of neonatal cardiomyocytes [35,
36] and adult cells [23,24,37] measured using microscopy or spectro-
photometers. The maximum increase in [Na+]i in cardiomyocytes in-
duced by corticosteroids was approximately 2.5 mM, which is a
slightly smaller alteration than that previously reported in heart failure
models [2–5]. This glucocorticoid-induced modest increase in [Na+]i
would have an impact on the subsequent development of cardiac
pathology.
In the present study, we also conﬁrmed that glucocorticoids induce
hypertrophy in cardiomyocytes via GR. Chronic treatment with physio-
logical concentrations of corticosteroids and supraphysiological concen-
trations of aldosterone upregulated the hypertrophic gene expression
as well as the incidence of morphological changes, in agreement with
the ﬁndings of previous reports [19,21,26,29,38–41]. Moreover, the
corticosteroid-induced hypertrophic gene expression levels were posi-
tively and signiﬁcantly associated with the level of [Na+]i, indicating
that elevated [Na+]i is involved in the pathogenesis of hypertrophy. Pre-
viously, an ionophore-induced small increase in [Na+]i has been report-
ed to activate the hypertrophic gene expression via SIK 1 in a myocyte
cell line [7]. That study showed that [Na+]i is an independent regulator
of the transcription and activation of the gene expression in an atrial
myocyte cell line. These results indicate that small increases in [Na+]i
induce cardiac hypertrophy, although further investigation is needed
to clarify whether the glucocorticoid-induced elevation of [Na+]i affects
the hypertrophic gene expression via the SIK1 pathway and whether
this phenomenon is applicable to ventricular cells.
[Na+]i is determined by the balance between Na+ inﬂux and efﬂux.
There are several pathways for Na+ entry into cells, including the NCX,
NHE, NKCC, and Na+/HCO3− cotransporter and Na+ channels [1,6]. In
the present study, short-term exposure (b6 h) to dexamethasone did
not increase [Na+]i (data not shown), and the glucocorticoid-induced
elevation in [Na+]i was a GR-dependent genomic reaction. These results
suggest that GR signaling modiﬁes the expression of transporters that
regulate [Na+]i. In this study, we found that chronic treatment with
dexamethasone induced the NCX1 expression at both the mRNA andFig. 5. Effects of glucocorticoids on the expressions of NCX1, NHE-1, and NKCC1. NRVMwere tr
48h. A: themRNA levels ofNCX1,NHE-1 andNKCC1 in theNRVMwere determined using real-ti
experiments. Dex, 100 nM of dexamethasone; RU, 1 μM of RU486. *P b 0.05 versus control gro
immunoblotting. The data represent the mean ± SEM of six independent experiments. *P b 0
in the dexamethasone-treated NRVM. NRVM were treated with 100 nM of dexamethasone for
(closed circles) of NCX1 at each time point are indicated. The data represent the mean ± SEM oprotein levels in a dose-dependent manner; this effect was abrogated
by aGR blocker. However, chronic dexamethasone treatment did not af-
fect the NKCC1mRNA expression or NHE-1 protein level (NHE-1mRNA
was slightly downregulated by 100 nMof dexamethasone). NCX, which
transports three Na+ ions in exchange for one Ca2+ ion, is the main
route for Na+ inﬂux in resting cardiac cells, and NCX1 is the major iso-
form in cardiomyocytes [42]. Taken together, we speculate that NCX1
is involved in the glucocorticoid-induced elevation of [Na+]i. On the
other hand, NCX has been reported to be highly expressed in late fetal
and neonatal rat hearts, decreasing to an adult level for RNA by
20 days after birth [43]. Therefore, the involvement of NCX in [Na+]i
handling and hypertrophy in NRVM may be different from that ob-
served in adult models. Further studies are needed to conﬁrm the con-
tribution of NCX1 in the glucocorticoid-induced alteration of [Na+]i in
cardiomyocytes.
5. Conclusions
We observed a signiﬁcant role of corticosteroids in regulating [Na+]i
via the GR pathway in cardiomyocytes. We also conﬁrmed that
glucocorticoids induce hypertrophy in cardiomyocytes via GR. The
corticosteroid-induced elevation of [Na+]i was closely and signiﬁcantly
associatedwith the hypertrophic gene expression. The dexamethasone-
induced upregulation of NCX1 is partly involved in the glucocorticoid-
induced alteration of [Na+]i in cardiomyocytes. These results provide
new insight into themechanisms bywhich glucocorticoid excesswithin
a physiological concentration contributes to the development of cardiac
pathology.
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